Under the Securities Exchange Act of 1934
(Amendment No. 3)

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

With a copy to:

Craig A. Roeder

Baker & McKenzie LLP

300 Randolph Street

Chicago, Illinois 60601

(312) 861-8000

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

2

3

4

Item 1.                                    Security and Issuer.

This Amendment No. 3 to Schedule 13D (this “Amendment No. 3”) relates to the ordinary shares, nominal value €0.01 per share (the “Ordinary Shares”), of Mylan N.V., public limited company (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Issuer”), and amends the Statement on Schedule 13D filed by Abbott Laboratories (“Abbott”), Abbott Established Products Holdings (Gibraltar) Limited (“Abbott Gibraltar”), Abbott Investments Luxembourg S.à r.l. (“Abbott Luxembourg” and together with Abbott and Abbott Gibraltar, the “Reporting Persons” and each, a “Reporting Person”) and Laboratoires Fournier S.A.S. on March 6, 2015, as amended by Amendment No. 1 thereto filed by the Reporting Persons and Laboratoires Fournier S.A.S. on April 6, 2015 and Amendment No. 2 thereto filed by the Reporting Persons on April 10, 2015 (as so amended, the “Initial Statement”). Except as specifically provided herein, this Amendment No. 3 does not modify any of the information previously reported in the Initial Statement. Capitalized terms used but not defined in this Amendment No. 3 have the respective meanings set forth in the Initial Statement.

Item 6.                                    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

This Amendment No. 3 amends Item 6 of the Initial Statement by inserting the following after the last paragraph of Item 6:

“On June 16, 2015, Abbott issued a press release affirming its continued support for the Issuer’s  growth strategy by stating its intent to vote its 14.5 percent stake in the Issuer in favor of the Issuer’s proposed acquisition of Perrigo Company plc.  A copy of Abbott’s press release is attached as Exhibit A and is incorporated herein by reference.”

Item 7.                                    Material to Be Filed as Exhibits.

The following documents are filed as exhibits to this Statement:

5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 18, 2015

6

Exhibit A

News Release

Abbott Affirms its Support for Mylan Standalone Strategy and Will Vote its Mylan Shares in Favor of Mylan’s Proposed Acquisition of Perrigo

ABBOTT PARK, Ill., June 16, 2015 — Abbott today confirmed its continued support for Mylan N.V’s growth strategy by stating its intent to vote its 14.5 percent stake in Mylan in favor of Mylan’s proposed acquisition of Perrigo.

“We chose Mylan to acquire our developed markets branded generics pharmaceuticals because its scale and breadth across critical distribution channels, broad and diverse portfolio, and commitment to patients and product quality strongly positions it for success in the years to come,” said Miles D. White, chairman and chief executive officer, Abbott. “As both Mylan’s largest shareholder and its partner through our continued manufacturing relationships, Abbott has considered the entire situation and we believe Mylan’s standalone strategy and acquisition of Perrigo will further enhance its platform, is strategically compelling, value enhancing for shareholders, and offers a clear path to completion. In light of these factors, we will be voting in favor of the Perrigo transaction.”

About Abbott:

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 73,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Abbott Media:

Scott Stoffel, (224) 668-5201

Abbott Financial:

Scott Leinenweber, (224) 668-0791